...
首页> 外文期刊>World Journal of Surgical Oncology >Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases
【24h】

Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases

机译:通过术前化疗诱导的脾膨胀是一种有用的指标,用于预测结直肠肝转移后的切除后预测肝脏再生

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Conversion chemotherapy may downsize unresectable colorectal liver metastases (CRLMs), but may cause liver injury and splenic enlargement. The effect of preoperative chemotherapy on liver regeneration after liver resection remains undetermined. The aim of this study was to examine whether splenic enlargement induced by preoperative chemotherapy is an indicator to identify high-risk patients for impaired liver regeneration and liver dysfunction after resection. We retrospectively reviewed 118 Japanese patients with CRLMs. Fifty-one patients had conversion chemotherapy. The other 67 patients underwent up-front liver resection. We clarified effects of conversion chemotherapy on splenic volume, liver function, and postoperative liver regeneration. Perioperative outcome was also analyzed. A ratio of the splenic volume before and after chemotherapy (SP index) in the oxaliplatin-based chemotherapy group was significantly greater than other chemotherapy groups after 9 or more chemotherapy cycles. Patients whose SP index was 1.2 or more had significantly higher indocyanine green retention rate at 15?min (ICG-R15) than patients without chemotherapy. Analyses of covariance showed liver regeneration rate after resection was decreased in patients whose SP index was 1.2 or more. The incidence of postoperative liver dysfunction in patients whose SP index was 1.2 or more was significantly greater than patients without chemotherapy. Multivariate analysis showed SP index was a significant predictive factor of impaired liver regeneration. Splenic enlargement induced by preoperative chemotherapy was a useful indicator for impaired liver regeneration after resection and a decision-making tool of treatment strategy for unresectable CRLMs.
机译:转化化疗可以使不可切除的结直肠肝转移(CRLMS)缩小,但可能导致肝损伤和脾脏扩大。术前化疗对肝切除后肝再生仍未确定的影响。本研究的目的是检查术前化疗诱导的脾肠病是否是鉴定高危患者在切除后识别高危肝再生和肝功能障碍的指标。我们回顾性地审查了118名日本患者的CRLMS。五十一名患者进行了转化化疗。另一种67名患者接受了上前肝切除术。我们澄清了转化化疗对脾体积,肝功能和术后肝再生的影响。还分析了围手术期结果。在奥沙利铂的化疗组中化疗(SP指数)之前和之后的脾剧性比例明显大于9或更多化疗循环后的其他化疗组。 SP指数为1.2或更多的患者在15?min(ICG-R15)的吲哚菁绿保持率明显高于没有化疗的患者。在SP指数为1.2或更高的患者中,转化后的协方差分析显示出肝再生率。患者术后肝功能障碍的发病率为1.2或更多的患者显着大于没有化疗的患者。多变量分析显示SP指数是肝再生受损的显着预测因素。术前化疗诱导的脾脏扩大是切除后肝再生受损的有用指标,以及用于不可切除的CRLMS的治疗策略的决策工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号